Natural history of hepatitis C and outcomes following liver transplantation

Clinics in Liver Disease

Volumn 7, Issue 3, 2003, Pages 585-602

  Charlton, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; GANCICLOVIR; HEPATITIS C ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E2; OKT 3; RIBAVIRIN; UNCLASSIFIED DRUG;

CAUSE OF DEATH; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT FAILURE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER FAILURE; LIVER GRAFT; LIVER TRANSPLANTATION; MONOTHERAPY; REVIEW; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; VIREMIA;

EID: 0042835566     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00046-1     Document Type: Review

References (85)

1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Hepatology 1998;28:390A.
2. Ascher NL, Lake JR, Emond J, et al. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:S24-7.
3. Boker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25:203-10.
4. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29:1220-6.
5. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. [see comments] N Engl J Med 1996;334:815-20.
6. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995;22:1-9.
7. Prieto M, Berenguer M, Rimola A, et al. Liver transplantation in hepatitis C. A Spanish multicentre experience. Eur J Gastroenterol Hepatol 1998;10:771-6.
8. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-22.
9. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-77.
10. Guerrero RB, Batts KP, Burgart LJ, et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000;13:229-37.
11. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7.
12. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-30.
13. Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Reviews 1996;2:219-28.
14. O'Reilly PM, Rosen HR, Shackleton CR, et al. Causes of graft loss following liver transplantation for chronic hepatitis C. Transplant Proc 1997;29:526-8.
15. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
16. Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-43.
17. Gayowski T, Singh N, Marino IR, et al. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997;64:422-6.
18. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-6.
19. Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996;24:1041-6.
20. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. [see comments] Gastroenterology 2002;122:889-96.
21. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
22. Lim HL, Lau GK, Davis GL, et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 1994;106:248-51.
23. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996;23:971-6.
24. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-84.
25. Gordon FD, Poterucha JJ, Germer J, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997;63:1419-23.
26. Sanchez-Fueyo A, Gimenez-Barcons M, Puig-Basagoiti F, et al. Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J Med Virol 2001;65:266-75.
27. Sullivan DG, Wilson JJ, Carithers RLJ, et al. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998;72:10036-43.
28. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-44.
29. Martell M, Esteban JI, Quer J, et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 1994;68:3425-36.
30. Pessoa MG, Bzowej N, Berenguer M, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999;30:1513-20.
31. Cotler SJ, Gaur LK, Gretch DR, et al. Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens 1998;52:435-43.
32. Prieto M, Nicolas D, Rayon JM, Berenguer M, Carrasco D, Berenguet J. Donor-recipient HLA matching does not predict accelerated progression of hepatitis C following liver transplantation in genotype 1b patients. Hepatology 2000;32(4):261A.
33. Rosen HR, Hinrichs DJ, Gretch DR, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. [see comments] Gastroenterology 1999;117:926-32.
34. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-7.
35. Gane EJ, Tibbs CJ, Ramage JK, et al. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995;8:61-4.
36. Aljumah AA, Cattral MS, Greig PD, et al. Long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplant Proc 1997;29:514.
37. Giostra E, Kullak-Ublick GA, Keller W, et al. Ribavrin/Interferon-alfa sequential treatment of recurrent hepatitis C after liver transplantation. Hepatology 2001;34:611A.
38. Casanovas T, Ramos E, Serrano T, et al. Pilot study with the combination of interferon alfa and ribavirin for recurrent post-liver transplantation hepatitis C. Causes of treatment failure in two different populations. Hepatology 2001;34:291A.
39. Gotz G, Schon MR, Haefker A, et al. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc 1998;30 2104-6.
40. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transplantation 2001;7:181-90.
41. Fischer L, Sterneck M, Valentin-Gamazo C, et al. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha. Transplant Proc 1999;31:494-5.
42. Nowicki MJ, Ahmad N, Heubi JE, et al. The prevalence of hepatitis C virus (HCV) in infants and children after liver transplantation. Dig Dis Sci 1994;39:2250-4.
43. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation [see comments] Hepatology 1997;26:500-4.
44. de Vera ME, Smallwood GA, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-86.
45. Menon KVN, Poterucha JJ, El-Amin OA, et al. Treatment of posttransplant recurrence of hepatitis C infection with interferon and ribavirin - lessons on tolerability and efficacy. Liver Transplantation 2002;8:515-20.
46. Manzarbeitia C, Teperman L, Chalasani N, et al. 40kDA Peginterferon alfa-2a (Pegasys) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial. Hepatology 2001;34:406A.
47. Neff G, Montalbano M, Lee Y, et al. Preliminary treatment results of liver transplantation recipients with recurrent hepatitis C virus nonresponsive to interferon alpha2B and ribavirin using combination pegylated interferon alpha 2B with ribavirin. Hepatology 2002;36:183A.
48. Khatib MA, Arenas JI, Carey E, et al. Treatment with combination of PEG IFN alfa 2B and ribavirin suppresses viral replication in liver transplantation recipients with recurrent HCV hepatitis. Hepatology 2002;36:183A.
49. Ferenci P, Peck-Radosavljevic M, Vogel W, et al. 40kDA Peginterferon alfa-2a (Pegasys) in post-liver transplant recipients with established recurrent hepatitis C: Preliminary results of a randomized mulitcenter trial. Hepatology 2001;34:406A.
50. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-9.
51. Pirenne J, Declauwe H, Aerts R, et al. Patients transplanted for hepatitis C should not receive organs from older donors. Hepatology 2001;34:409A.
52. Ghobrial RM, Amherst F, Farmer DG, et al. Rapid and severe early HCV recurrence following adult living donor liver transplantation. American Journal of Transplantation 2002;2:163.
53. Taniguchi M, Wachs M, Bak T, Trotter J, et al. Hepatitis C recurrence in living donor liver transplantation. American Journal of Transplantation 2002;2:138.
54. Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. [see comments] Liver Transplantation 2000;6:407-12.
55. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transplantation & Surgery 1999;5(Suppl 14):107-14
56. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-4.
57. Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. [see comments] Am J Gastroenterol 1997;92:1453-7.
58. Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002;35:974-81.
59. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-6.
60. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-25.
61. Crippin JS, McCashland TM, Terrault NA, Sheiner PA, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-5.
62. Everson GT, Trouillot T, Trotter J, Skilbred LA, et al. Treatment of decompensated cirrhotics with a low-accelerating dose regimen (LADR) of interferon-alfa-2B plus ribavirinn: Safety and Efficacy. Hepatology 2000;32:595A.
63. Heathcote J, Shiffman ML, Cooksley G, et al. Multinational evaluation of the efficacy and safety of once-weekly peginterferon alfa 2A (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis. Hepatology 1999;30:316A.
64. Garcia-Retortillo M, Forns X, Suarez F, et al. Efficacy and safety of combined interferon and ribavirin therapy in cirrhotic patients infected with hepatitis C virus (HCV) awaiting liver transplantation. Hepatology 2002;36:177A.
65. Feray C, Gigou M, Samuel D, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998;128:810-6.
66. Willems B, Ede M, Marotta P, et al. Anti-HCV human immunoglobulin for the prevention of graft infection in HCV-related liver transplantation - a pilot study. J Hepatol 2002;36:32.
67. Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-9.
68. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-8.
69. Quadri R, Giostra E, Roskams T, et al. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 2002;73:373-8.
70. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998;339(19):1493-9.
71. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. [see comments] N Engl J Med 1998;339:1485-92.
72. Kapur A, Rodriguez MJ, Schecter P, Tzakis A, Schiff ER. Interferon alfa and ribavirin in established post liver transplant recurrent hepatitis C infection. Gastroenterology 1998;114:A1268.
73. Mazzaferro V, Regalia E, Pulvirenti A, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-21.
74. Lavezzo B, Rizzetto M, Smedile A, et al. Combination therapy of interferon alfa 2b and ribavirin for recurrent hepatitis C after liver transplantation. J Hepatol 1999;30:67.
75. Mazzaferro V, Regalia E, Pulvirenti A, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-21.
76. Wasserman R, Brau N, Hassanein T, et al. Once weekly Epoetin alfa increases hemogolbin and decreases ribavirin dose reductions among HCV-infected patients who develop anemia on ribavirin/interferon alfa 2b therapy. Hepatology 2000;32:833A.
77. Heathcote J, Shiffman ML, Cooksley GW, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-9.
78. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
79. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40kDa) interferon alfa-2a (Pegasys) in combination with ribavirin - efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 2001;120:A55.
80. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
81. Kamal SM, Fehr J, Roesler B, et al. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-83.
82. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995;22:1084-9.
83. Vargas V, Charco R, Castells L, et al. Alpha-interferon for acute hepalitis C in liver transplant patients. Transplant Proc 1995;27:1222-3.
84. Samuel D, Bizollon T, Feray C, et al. Combination of interferon alfa 2-B plus ribavirin for recurrent HCV infection after liver transplantation: A randomized controlled study. Hepatology 2000;32:542A.
85. Willner IR, Chavin KD, Rogers J, Baliga P, Reuben A. Combination interferon-ribavirin is ineffective and poorly tolerated by liver transplant recipients with genotype 1 recurrent hepatitis C. Hepatology 2000;32:290A.